Another one of Bristol-Myers' PD-1/CTLA-4 combo studies bites the dust
Bristol-Myers Squibb can move another Opdivo/Yervoy combo study to the loss column.
In its quarterly review out Thursday morning, the troubled giant noted briefly …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
